Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
GENTACIDIN vs BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibiting protein synthesis.
Bacitracin zinc inhibits bacterial cell wall synthesis by interfering with dephosphorylation of the lipid carrier that transports peptidoglycan precursors. Neomycin sulfate and polymyxin B sulfate are aminoglycoside and polypeptide antibiotics, respectively; neomycin binds to 30S ribosomal subunit and causes misreading of m RNA, while polymyxin B disrupts bacterial cell membrane permeability by interacting with phospholipids.
Treatment of serious gram-negative bacterial infections,Combination therapy for enterococcal endocarditis,Brucellosis,Tularemia
Topical treatment of bacterial infections of the skin and eye (e.g., conjunctivitis, keratitis, blepharitis),Prophylaxis of minor wounds, cuts, and abrasions
5-7 mg/kg IV every 24 hours.
Apply topically (ointment or cream) to affected area 1-3 times daily. For ophthalmic use, instill 1-2 drops into affected eye(s) every 3-4 hours.
2-3 hours in adults with normal renal function; extended to 24-48 hours in anuria or severe renal impairment, requiring dose adjustment.
Neomycin: 2-3 h; polymyxin B: 4.5-6 h; bacitracin: 1.5 h. Combined: effectively ~2-6 h depending on renal function; clinical context: prolonged with renal impairment.
Primarily excreted unchanged by glomerular filtration; minimal hepatic metabolism.
Not systemically absorbed after topical administration; no significant metabolism.
Renal: 95-98% unchanged via glomerular filtration; biliary/fecal: <2%.
Neomycin: ~99% renal; polymyxin B: ~60% renal, 40% fecal; bacitracin: mainly renal (over 90%). Combined: renal (predominant), with minor biliary/fecal contribution (polymyxin B).
10-20% bound to albumin.
Neomycin: 0-20%; polymyxin B: 60-80% (alpha-1-acid glycoprotein, albumin); bacitracin: <5%. Combined: ~40-50% bound overall.
0.2-0.4 L/kg, indicating distribution primarily in extracellular fluid.
Neomycin: ~0.25 L/kg; polymyxin B: ~0.5 L/kg; bacitracin: ~0.3 L/kg. Combined Vd ~0.3-0.5 L/kg, reflecting limited distribution mainly to extracellular fluid.
IM: 90-100%; topical: negligible systemic absorption (<10%); oral: <1%.
Topical/ophthalmic/otic: negligible systemic absorption (<0.1%).
GFR >60 m L/min: 5-7 mg/kg q24h; GFR 30-59: 3-4 mg/kg q24-48h; GFR 15-29: 2-3 mg/kg q48-72h; GFR <15: 1-2 mg/kg q72-96h or after dialysis.
No systemic absorption with typical topical use; no adjustment necessary. For extensive use on damaged skin, monitor renal function and adjust if needed; no specific GFR-based guidelines.
No adjustment required for Child-Pugh A, B, or C; monitor levels if severe hepatic impairment.
No adjustment needed for topical use. No systemic effects expected.
Neonates: 4-5 mg/kg IV q24h; Infants/Children: 5-7.5 mg/kg IV q24h; adjust per therapeutic drug monitoring.
Same as adult dosing for topical use. For neonates, use with caution on large surface areas; avoid prolonged use.
Initiate at lower end (5 mg/kg IV q24h) and adjust based on renal function; monitor serum creatinine and drug levels closely.
No specific age-related adjustments. Use with caution on fragile skin; apply sparingly to avoid systemic absorption.
WARNING: Nephrotoxicity and ototoxicity, even at therapeutic doses; monitor renal function and hearing. Neurotoxicity may occur. Avoid concurrent use with other nephrotoxic or ototoxic drugs.
None.
Monitor renal function, serum drug levels, and audiometric tests. Use caution in elderly, dehydrated, or renally impaired patients. Prolonged use may lead to superinfection.
Prolonged use may result in overgrowth of nonsusceptible organisms including fungi.,Neomycin is ototoxic and nephrotoxic if absorbed systemically (e.g., applied to large areas of damaged skin).,Avoid contact with eyes other than for ophthalmic use.,Cross-allergenicity among aminoglycosides exists.
Hypersensitivity to gentamicin or any aminoglycoside; myasthenia gravis; history of ototoxicity or nephrotoxicity with prior aminoglycoside use.
Hypersensitivity to any component of the product.,Otic use if tympanic membrane is perforated (risk of ototoxicity).
No specific food interactions; maintain adequate hydration to reduce renal risk.
No known food interactions with topical application.
Gentamicin is an aminoglycoside antibiotic. Animal studies have shown evidence of fetal harm (nephrotoxicity, ototoxicity). There are no adequate well-controlled studies in pregnant women. Gentamicin crosses the placenta. Risk cannot be ruled out. The drug should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. First trimester: Theoretical risk of ototoxicity and nephrotoxicity. Second and third trimesters: Potential for fetal ototoxicity (eighth cranial nerve) and nephrotoxicity, especially with prolonged or high-dose therapy.
No evidence of teratogenicity in first trimester; animal studies show no fetal harm. Second and third trimester risk is low due to minimal systemic absorption from topical use. No known association with congenital anomalies.
Gentamicin is excreted into human milk in low concentrations. The milk-to-plasma (M/P) ratio is approximately 0.2-0.4. Oral bioavailability in infants is poor, so systemic effects are unlikely. However, due to potential for alteration of infant gut flora and direct effects (e.g., diarrhea, allergic reactions), caution is advised. The American Academy of Pediatrics considers gentamicin compatible with breastfeeding. Use only if clearly needed, and monitor infant for signs of gastrointestinal disturbance.
Minimal systemic absorption suggests negligible excretion into breast milk; M/P ratio not determined. Considered compatible with breastfeeding by AAP; avoid application to breast area to prevent infant ingestion.
Pregnancy may increase glomerular filtration rate, leading to lower serum concentrations. Gentamicin is primarily renally eliminated. Dose adjustments based on renal function and therapeutic drug monitoring are essential. Increased doses or shortened intervals may be required to maintain therapeutic levels. Monitor peak and trough concentrations closely, adjusting dose and interval to achieve target levels (peak 4-10 μg/m L, trough <2 μg/m L).
No dosage adjustment required for topical use; systemic absorption is negligible. Use standard dosing as per non-pregnant adults.
Gentacidin (gentamicin sulfate) is an aminoglycoside antibiotic; monitor peak and trough levels to avoid nephrotoxicity and ototoxicity. Adjust dose in renal impairment. Avoid concurrent use with other nephrotoxic drugs (e.g., NSAIDs, vancomycin).
OTC triple antibiotic ointment; avoid use on deep wounds, puncture wounds, or animal bites due to risk of toxicity and lack of efficacy. Neomycin carries the highest risk of allergic contact dermatitis among topical antibiotics; consider patch testing if prolonged use needed. Polymyxin B can cause neurotoxicity and nephrotoxicity if applied to large wounds or damaged skin. Not for use in eyes, ears, or mucous membranes. Do not exceed 7 days of continuous use.
Complete the full course even if symptoms improve.,Report hearing loss, tinnitus, dizziness, or decreased urine output immediately.,May cause injection site pain; rotate sites if applicable.,Avoid alcohol during therapy.
Clean the affected area before applying a thin layer of ointment 1-3 times daily.,Do not use on large areas of skin, deep cuts, puncture wounds, or animal bites unless directed by a doctor.,Do not apply to eyes, nose, mouth, or inside ears.,Stop use and consult a doctor if rash or allergic reaction develops, condition worsens, or persists for more than 7 days.,Keep out of reach of children; seek medical attention if accidentally ingested.
No interactions on record
"Cisatracurium, a non-depolarizing neuromuscular blocking agent (NMBA), competitively blocks nicotinic acetylcholine receptors at the neuromuscular junction, causing skeletal muscle paralysis. Polymyxin B, a polypeptide antibiotic, can potentiate this neuromuscular blockade by reducing presynaptic acetylcholine release and stabilizing postsynaptic membranes, leading to prolonged and enhanced neuromuscular blockade. This interaction increases the risk of prolonged muscle paralysis, respiratory depression, and apnea, especially in patients with renal impairment or those receiving other NMBAs."
"Mecamylamine, a ganglionic blocking agent, potentiates the neuromuscular blocking effects of Polymyxin B, a polypeptide antibiotic. This interaction occurs through additive or synergistic inhibition of neuromuscular transmission, potentially leading to prolonged or intensified muscle relaxation, respiratory depression, and apnea. The clinical outcome may include enhanced toxicity, especially in patients with renal impairment or those receiving concurrent anesthetics or other neuromuscular blocking agents."
"Decamethonium, a depolarizing neuromuscular blocker, enhances the neuromuscular blocking effects of Polymyxin B, a polypeptide antibiotic that can also cause neuromuscular blockade via direct membrane stabilization and calcium channel inhibition. This additive pharmacodynamic interaction can lead to prolonged or enhanced muscle weakness, potentially resulting in respiratory paralysis and apnea. Clinically, this combination increases the risk of acute respiratory failure and may prolong recovery from neuromuscular blockade."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about GENTACIDIN vs BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE, answered by our medical review team.
GENTACIDIN is a Aminoglycoside Antibiotic that works by Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibiting protein synthesis.. BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE is a Aminoglycoside Antibiotic that works by Bacitracin zinc inhibits bacterial cell wall synthesis by interfering with dephosphorylation of the lipid carrier that transports peptidoglycan precursors. Neomycin sulfate and polymyxin B sulfate are aminoglycoside and polypeptide antibiotics, respectively; neomycin binds to 30S ribosomal subunit and causes misreading of m RNA, while polymyxin B disrupts bacterial cell membrane permeability by interacting with phospholipids.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between GENTACIDIN and BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE depend on the specific clinical indication. These are both Aminoglycoside Antibiotic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of GENTACIDIN is: 5-7 mg/kg IV every 24 hours.. The standard adult dose of BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE is: Apply topically (ointment or cream) to affected area 1-3 times daily. For ophthalmic use, instill 1-2 drops into affected eye(s) every 3-4 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between GENTACIDIN and BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. GENTACIDIN is classified as Category C. Gentamicin is an aminoglycoside antibiotic. Animal studies have shown evidence of fetal harm (nephrotoxicity, ototoxicity). There are no adequate well-controlled studies in pregnan. BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE is classified as Category A/B. No evidence of teratogenicity in first trimester; animal studies show no fetal harm. Second and third trimester risk is low due to minimal systemic absorption from topical use. No . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.